Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection following foot and ankle surgery : a subanalysis of data captured from the UK Foot and Ankle Thromboembolism (FATE) audit.

The bone & joint journal·2026
Same author

Identification of Reliable Biomarkers for ALS Through Machine Learning Approach.

Studies in health technology and informatics·2026
Same author

Identification of Potential Biomarkers in ASD Integrating RNA Seq Data and Machine Learning Approaches.

Studies in health technology and informatics·2026
Same author

D-dimer levels in acute exacerbation of asthma among children: A correlation study.

Bioinformation·2026
Same author

Accuracy Is Not Enough: Reasoning and Reference Reliability in Orthopaedic Large Language Model (LLM) Applications.

Cureus·2026
Same author

Self-Integrating Multifunctional Amyloidogenic Protein-Fenugreek Composite Hydrogel Patch and Ointment for Accelerated Deep Muscle Wound Healing in Rabbit Model.

ACS applied bio materials·2026

Related Experiment Video

Updated: Jun 29, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.5K

Pharmacokinetic Prediction of Repurposed Drugs for PDAC Using Artificial Intelligence.

Pragya Pragya1, Shashwat Singh1, Bhuvaneshwari Balasubramaniam2

  • 1Computational Neuroscience and Biology Lab, School of Biomedical Engineering, Indian Institute of Technology (BHU) Varanasi, Varanasi 221005, India.

ACS Omega
|April 13, 2026
PubMed
Summary

This study introduces an AI framework to predict pharmacokinetic properties of drugs for pancreatic cancer, accelerating drug repurposing. Combining molecular descriptors with AI models effectively models drug properties for improved cancer treatment.

More Related Videos

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.2K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Related Experiment Videos

Last Updated: Jun 29, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.5K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

13.2K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Area of Science:

  • Computational chemistry and bioinformatics
  • Artificial intelligence in drug discovery
  • Oncology and pharmaceutical sciences

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high drug resistance.
  • Drug repurposing offers a faster route to new treatments for PDAC.
  • Predicting pharmacokinetic (PK) properties is crucial for effective drug development.

Purpose of the Study:

  • To develop and validate an AI framework for predicting PK properties of repurposed drugs for PDAC.
  • To explore the utility of different molecular descriptors and AI models for PK property prediction.
  • To assess the performance of the AI models on both PDAC-specific and general datasets.

Main Methods:

  • Generated molecular features using RDKit, MACCS, and ECFP6 descriptors.
  • Obtained drug properties (absorption, distribution, metabolism, excretion, toxicity) from ADMETlab 3.0.
  • Constructed and evaluated AI models including MLP, RF, XGB, and 1D-CNN.

Main Results:

  • The best-performing AI models and molecular descriptor combinations varied across different PK properties.
  • Models achieved notable performance metrics on both PDAC and Therapeutics Data Commons (TDC) datasets.
  • Specific models demonstrated high accuracy for predicting absorption, distribution, metabolism, excretion, and toxicity.

Conclusions:

  • Combining molecular fingerprints with AI is effective for modeling PK properties.
  • The developed AI framework can accelerate drug repurposing for PDAC and other diseases.
  • This approach holds significant potential for advancing pharmaceutical research and development.